• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: MICRO THERAPEUTICS, INC. DBA EV3 PIPELINE INTRACRANIAL ANEURYSM FLOW DIVERTER

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

MICRO THERAPEUTICS, INC. DBA EV3 PIPELINE INTRACRANIAL ANEURYSM FLOW DIVERTER Back to Search Results
Model Number NV UNK PIPELINE
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Edema (1820); Hemorrhage, Cerebral (1889); Therapeutic Response, Decreased (2271)
Event Date 02/26/2018
Event Type  Injury  
Manufacturer Narrative
If information is provided in the future, a supplemental report will be issued.
 
Event Description
Adam a. Dmytriw, nimer adeeb, ashish kumar, christoph j. Griessenauer, kevin phan, christopher s. Ogilvy, paul m. Foreman, hussain shallwani, nicola limbucci, salvatore mangiafico, caterina michelozzi, timo krings ,md, vitormendes pereira,md, charles c. Matouk, yuchen zhang, mark r. Harrigan, hakeem j. Shakir, adnan h. Siddiqui, elad i. Levy, leonardo renieri, christophe cognard, ajith j. Thomas, thomas r. Marotta. Flow diversion for the treatment of basilar apex aneurysms. Neurosurgery 83 (2018). Doi:10. 1093/neuros/nyx628. Background: flow diversion for basilar apex aneurysms has rarely been reported. Objective: to assess flow diversion for basilar apex aneurysms in a multicenter cohort. Methods: retrospective review of prospectively maintained databases at 8 academic institutions was performed from 2009 to 2016 to identify patients with basilar apex aneurysms treated with flow diversion. Clinical and radiographic data were analyzed. Results: sixteen consecutive patients (median age 54. 5 yr) underwent 18 procedures to treat 16 basilar apex aneurysms with either the pipeline embolization device (medtronic inc, (b)(4)) or flow redirection endoluminal device (microvention, (b)(4)). Five aneurysms (31. 3%) were treated in the setting of subarachnoid hemorrhage. Seven aneurysms (43. 8%) were treated with flow diversion alone, while 9 (56. 2%) underwent flow diversion and adjunctive coiling. At a median follow-up of 6 mo, complete (100%) and near-complete (90%-99%) occlusion was noted in 11 (68. 8%) aneurysms. Incomplete occlusion occurred more commonly in patients treated with flow diversion alone compared to those with adjunctive coiling. Patients with partial occlusion were significantly younger. Retreatment with an additional flow diverter and adjunctive coiling occurred in 2 aneurysms with wide necks. There was 1 mortality in a patient (6. 3%) who experienced posterior cerebral artery and cerebellar strokes as well as subarachnoid hemorrhage after the placement of a flow diverter. Minor complications occurred in 2 patients (12. 5%). Conclusion: flow diversion for the treatment of basilar apex aneurysms results in acceptable occlusion rates in highly selected cases. Both primary flow diversion and rescue after failed clipping or coiling resulted in a modified rankin scale score that was either equal or better than at presentation and the technology represents a viable alternative or adjunctive option. Reported events. A (b)(6) male was undergoing surgery to treat a saccular aneurysm with a maximum dimension of 35 mm. The patient had a nondependent territory intracerebral hemorrhage that resolved without impact on mrs. A (b)(6) male was undergoing surgery to treat a saccular aneurysm with a maximum dimension of 27 mm. The patient developed perianeurysmal edema and mass effect; the only minor complication that affected mrs. Retreatment occurred with an additional flow diverter. A (b)(6) female was undergoing surgery to treat a saccular aneurysm with a maximum dimension of 10 mm. The patient experienced incomplete occlusion and required retreatment with an additional flow diverter.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand NamePIPELINE
Type of DeviceINTRACRANIAL ANEURYSM FLOW DIVERTER
Manufacturer (Section D)
MICRO THERAPEUTICS, INC. DBA EV3
9775 toledo way
irvine CA 92618
Manufacturer (Section G)
MICRO THERAPEUTICS, INC. DBA EV3
9775 toledo way
irvine CA 92618
Manufacturer Contact
katcha taylor
9775 toledo way
irvine, CA 92618
9496801345
MDR Report Key10100847
MDR Text Key200971951
Report Number2029214-2020-00504
Device Sequence Number1
Product Code OUT
Combination Product (y/n)N
Reporter Country CodeCA
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign,health professional,l
Reporter Occupation
Type of Report Initial
Report Date 05/29/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received05/29/2020
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator
Device Model NumberNV UNK PIPELINE
Device Catalogue NumberNV UNK PIPELINE
Device Lot NumberNOT-REP
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA?
Event Location No Information
Date Manufacturer Received05/27/2020
Was Device Evaluated by Manufacturer? No Answer Provided
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial

Patient Treatment Data
Date Received: 05/29/2020 Patient Sequence Number: 1
-
-